Search

Your search keyword '"Raphael, Martine F."' showing total 45 results
Start Over Author "Raphael, Martine F."
45 results on '"Raphael, Martine F."'

4. Experiences with a national team-based learning program for advance care planning in pediatric palliative care

Author

Palliatieve Zorg, Intensive care patientenzorg, Expertisecentrum Alg., Cancer, Child Health, Engel, Marijanne, Fahner, Jurrianne C., Hennus, Marije P., Brounen, Marie-José, van Capelle, Carine, de Groot, Marinka A.R., Hermans-Peters, Marion, Hofman, Suzanne C., Joosen, Cindy, Lalbahadoersing-Jharap, Sarmila, Maebe, Sofie, Michiels, Erna M.C., Miedema, Suzanna, Raphael, Martine F, Schieving, Jolanda H., de Weerd, Willemien, Kars, MC, Palliatieve Zorg, Intensive care patientenzorg, Expertisecentrum Alg., Cancer, Child Health, Engel, Marijanne, Fahner, Jurrianne C., Hennus, Marije P., Brounen, Marie-José, van Capelle, Carine, de Groot, Marinka A.R., Hermans-Peters, Marion, Hofman, Suzanne C., Joosen, Cindy, Lalbahadoersing-Jharap, Sarmila, Maebe, Sofie, Michiels, Erna M.C., Miedema, Suzanna, Raphael, Martine F, Schieving, Jolanda H., de Weerd, Willemien, and Kars, MC

Published
2024

5. Mental Health of School-Aged Children Treated with Propranolol or Atenolol for Infantile Hemangioma and Their Parents

Author

Hermans, Mireille M., Schappin, Renske, De Laat, Peter C.J., Mendels, Elodie J., Breur, Johannes M.P.J., Langeveld, Hester R., Raphael, Martine F., De Graaf, Marlies, Breugem, Corstiaan C., De Wildt, Saskia N., Okkerse, Jolanda M.E., Pasmans, Suzanne G.M.A., Rietman, André B., Hermans, Mireille M., Schappin, Renske, De Laat, Peter C.J., Mendels, Elodie J., Breur, Johannes M.P.J., Langeveld, Hester R., Raphael, Martine F., De Graaf, Marlies, Breugem, Corstiaan C., De Wildt, Saskia N., Okkerse, Jolanda M.E., Pasmans, Suzanne G.M.A., and Rietman, André B.

Abstract

Background: Infants with infantile hemangioma (IH) have been effectively treated with propranolol or atenolol. Concerns were raised about the mental health of these The trial registration: Netherlands Trial Register Trial NL7703.children at school age, due to central nervous system effects of propranolol and visible nature of IH. Objective: This study aimed to compare the mental health at school age of children treated with propranolol to children treated with atenolol for IHs and their parents. Methods: This two-centered cross sectional study included children aged =6 years and treated with either propranolol or atenolol for IH during infancy. Children’s outcomes were performance-based affect recognition (Dutch version of the Developmental Neuropsychological Assessment-II [NEPSY-II-NL]), parent-reported emotional and behavioral functioning (Child Behavioral Checklist [CBCL]), and health-related quality of life (KIDSCREEN27). Parents’ outcome was parenting stress (Parenting Stress Questionnaire [OBVL]). Results: Data of 105 children (36 propranolol, 69 atenolol; 6.0–11.8 years) were analyzed. Mental health outcomes did not differ between both ß-blocker groups. Although overall functioning was in line with norms, children presented specific problems concerning affect recognition, parent-reported attention, and social quality of life. Parents showed increased physical symptoms, depressive symptoms, and parent-child relationship problems. Conclusion: No difference in mental health at school age was found between children treated with propranolol or atenolol for IH. Although few overall mental health problems were found, specific problems require follow-up. Follow-up of children should be directed toward affect recognition, attention, and social functioning in daily life. Problems reported by parents could be ameliorated by mental health support during and after their in

Published
2024

6. Mental health of school-aged children treated with propranolol or atenolol for infantile hemangioma and their parents

Author

E&R onderzoek, Cardiologie onderzoek 1, Child Health, Circulatory Health, Regenerative Medicine and Stem Cells, MS Dermatologie/Allergologie, Infection & Immunity, Zorgeenheid Plastische Chirurgie Medisch, Hermans, Mireille M, Schappin, Renske, de Laat, Peter C J, Mendels, Elodie J, Breur, Johannes M P J, Langeveld, Hester R, Raphael, Martine F, de Graaf, Marlies, Breugem, Corstiaan C, de Wildt, Saskia N, Okkerse, Jolanda M E, Pasmans, Suzanne G M A, Rietman, André B, E&R onderzoek, Cardiologie onderzoek 1, Child Health, Circulatory Health, Regenerative Medicine and Stem Cells, MS Dermatologie/Allergologie, Infection & Immunity, Zorgeenheid Plastische Chirurgie Medisch, Hermans, Mireille M, Schappin, Renske, de Laat, Peter C J, Mendels, Elodie J, Breur, Johannes M P J, Langeveld, Hester R, Raphael, Martine F, de Graaf, Marlies, Breugem, Corstiaan C, de Wildt, Saskia N, Okkerse, Jolanda M E, Pasmans, Suzanne G M A, and Rietman, André B

Published
2024

7. Mental Health of School-Aged Children Treated with Propranolol or Atenolol for Infantile Hemangioma and Their Parents

Author

Hermans, Mireille M., primary, Schappin, Renske, additional, de Laat, Peter C.J., additional, Mendels, Elodie J., additional, Breur, Johannes M.P.J., additional, Langeveld, Hester R., additional, Raphael, Martine F., additional, de Graaf, Marlies, additional, Breugem, Corstiaan C., additional, de Wildt, Saskia N., additional, Okkerse, Jolanda M.E., additional, Pasmans, Suzanne G.M.A., additional, and Rietman, André B., additional

Published
2024
Full Text
View/download PDF

9. Prognostic Factors for Long-term Aesthetic Outcome of Infantile Haemangioma Treated with Beta-blockers

Author

Hermans, Mireille M., primary, Pasmans, Suzanne G.M.A., additional, De Graaf, Marlies, additional, Ragamin, Aviël, additional, Mendels, Elodie J., additional, Breur, Johannes M.P.J., additional, Langeveld, Hester R., additional, Raphael, Martine F., additional, De Laat, Peter C.J., additional, De Wildt, Saskia N., additional, Rietman, André B., additional, Breugem, Corstiaan C., additional, and Schappin, Renske, additional

Published
2023
Full Text
View/download PDF

10. Propranolol or atenolol for the management of infantile hemangioma: Implications for long-term health

Author

Hermans, Mireille M., primary, Pasmans, Suzanne G.M.A., additional, de Laat, Peter C.J., additional, Slieker, Martijn G., additional, Mendels, Elodie J., additional, de Graaf, Marlies, additional, Langeveld, Hester R., additional, Schappin, Renske, additional, Rietman, André B., additional, Breugem, Corstiaan C., additional, Breur, Johannes M.P.J., additional, de Wildt, Saskia N., additional, and Raphael, Martine F., additional

Published
2023
Full Text
View/download PDF

11. Prognostic Factors for Long-term Aesthetic Outcome of Infantile Haemangioma Treated with Beta-blockers

Author

Hermans, Mireille M., Pasmans, Suzanne G.M.A., De Graaf, Marlies, Ragamin, Aviël, Mendels, Elodie J., Breur, Johannes M.P.J., Langeveld, Hester R., Raphael, Martine F., De Laat, Peter C.J., De Wildt, Saskia N., Rietman, André B., Breugem, Corstiaan C., Schappin, Renske, Hermans, Mireille M., Pasmans, Suzanne G.M.A., De Graaf, Marlies, Ragamin, Aviël, Mendels, Elodie J., Breur, Johannes M.P.J., Langeveld, Hester R., Raphael, Martine F., De Laat, Peter C.J., De Wildt, Saskia N., Rietman, André B., Breugem, Corstiaan C., and Schappin, Renske

Abstract

Parents of infants treated with beta-blockers for infantile haemangioma are often concerned about the long-term aesthetic outcome. This cross-sectional study assessed the influence on the long-term aesthetic outcome of characteristics of the infantile haemangioma, the beta-blocker treatment, and the infant. The study included 103 children aged 6-12 years, treated with beta-blockers (propranolol or atenolol) for infantile haemangioma during infancy (age at treatment initiation ≤1 year) for ≥6 months. Dermatologists and parents scored the Patient Observer Scar Assessment Scale, and the child scored a visual analogue scale. Dermatologists identified whether telangiectasia, fibrofatty tissue, and atrophic scar tissue were present. The long-term aesthetic outcome of infantile haemangioma was judged more negatively by dermatologists and parents in case of a superficial component, ulceration, older age at treatment initiation, higher cumulative dose, and/or shorter follow-up time. According to children, infantile haemangioma located on the head had better aesthetic outcome than infantile haemangioma located elsewhere. Close monitoring, particularly of infantile haemangioma with a superficial component, is essential for early initiation of treatment, and to prevent or treat ulceration. These outcome data can support parental counselling and guide treatment strategy.

Published
2023

12. Propranolol or atenolol for the management of infantile hemangioma:Implications for long-term health

Author

Hermans, Mireille M., Pasmans, Suzanne G.M.A., de Laat, Peter C.J., Slieker, Martijn G., Mendels, Elodie J., de Graaf, Marlies, Langeveld, Hester R., Schappin, Renske, Rietman, André B., Breugem, Corstiaan C., Breur, Johannes M.P.J., de Wildt, Saskia N., Raphael, Martine F., Hermans, Mireille M., Pasmans, Suzanne G.M.A., de Laat, Peter C.J., Slieker, Martijn G., Mendels, Elodie J., de Graaf, Marlies, Langeveld, Hester R., Schappin, Renske, Rietman, André B., Breugem, Corstiaan C., Breur, Johannes M.P.J., de Wildt, Saskia N., and Raphael, Martine F.

Published
2023

13. Prognostic Factors for Long-term Aesthetic Outcome of Infantile Haemangioma Treated with Beta-blockers

Author

MS Dermatologie/Allergologie, Infection & Immunity, Cardiologie onderzoek 1, Child Health, Circulatory Health, Regenerative Medicine and Stem Cells, E&R onderzoek, Zorgeenheid Plastische Chirurgie Zorg, Hermans, Mireille M., Pasmans, Suzanne G.M.A., De Graaf, Marlies, Ragamin, Aviël, Mendels, Elodie J., Breur, Johannes M.P.J., Langeveld, Hester R., Raphael, Martine F., De Laat, Peter C.J., De Wildt, Saskia N., Rietman, André B., Breugem, Corstiaan C., Schappin, Renske, MS Dermatologie/Allergologie, Infection & Immunity, Cardiologie onderzoek 1, Child Health, Circulatory Health, Regenerative Medicine and Stem Cells, E&R onderzoek, Zorgeenheid Plastische Chirurgie Zorg, Hermans, Mireille M., Pasmans, Suzanne G.M.A., De Graaf, Marlies, Ragamin, Aviël, Mendels, Elodie J., Breur, Johannes M.P.J., Langeveld, Hester R., Raphael, Martine F., De Laat, Peter C.J., De Wildt, Saskia N., Rietman, André B., Breugem, Corstiaan C., and Schappin, Renske

Published
2023

14. Correction to: Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma (European Journal of Pediatrics, (2022), 182, 2, (757-767), 10.1007/s00431-022-04674-7)

Author

E&R onderzoek, Cardiologie onderzoek 1, Child Health, Circulatory Health, Regenerative Medicine and Stem Cells, Zorgeenheid Plastische Chirurgie Medisch, MS Dermatologie/Allergologie, Infection & Immunity, Hermans, Mireille M, Rietman, André B, Schappin, Renske, de Laat, Peter C J, Mendels, Elodie J, Breur, Johannes M P J, Langeveld, Hester R, de Wildt, Saskia N, Breugem, Corstiaan C, de Graaf, Marlies, Raphael, Martine F, Pasmans, Suzanne G M A, E&R onderzoek, Cardiologie onderzoek 1, Child Health, Circulatory Health, Regenerative Medicine and Stem Cells, Zorgeenheid Plastische Chirurgie Medisch, MS Dermatologie/Allergologie, Infection & Immunity, Hermans, Mireille M, Rietman, André B, Schappin, Renske, de Laat, Peter C J, Mendels, Elodie J, Breur, Johannes M P J, Langeveld, Hester R, de Wildt, Saskia N, Breugem, Corstiaan C, de Graaf, Marlies, Raphael, Martine F, and Pasmans, Suzanne G M A

Published
2023

15. Propranolol or atenolol for the management of infantile hemangioma: Implications for long-term health

Author

E&R onderzoek, Cardiologie patientenzorg, Child Health, Circulatory Health, MS Dermatologie/Allergologie, Infection & Immunity, Zorgeenheid Plastische Chirurgie Medisch, Cardiologie onderzoek 1, Regenerative Medicine and Stem Cells, Hermans, Mireille M, Pasmans, Suzanne G M A, de Laat, Peter C J, Slieker, Martijn G, Mendels, Elodie J, de Graaf, Marlies, Langeveld, Hester R, Schappin, Renske, Rietman, André B, Breugem, Corstiaan C, Breur, Johannes M P J, de Wildt, Saskia N, Raphael, Martine F, E&R onderzoek, Cardiologie patientenzorg, Child Health, Circulatory Health, MS Dermatologie/Allergologie, Infection & Immunity, Zorgeenheid Plastische Chirurgie Medisch, Cardiologie onderzoek 1, Regenerative Medicine and Stem Cells, Hermans, Mireille M, Pasmans, Suzanne G M A, de Laat, Peter C J, Slieker, Martijn G, Mendels, Elodie J, de Graaf, Marlies, Langeveld, Hester R, Schappin, Renske, Rietman, André B, Breugem, Corstiaan C, Breur, Johannes M P J, de Wildt, Saskia N, and Raphael, Martine F

Published
2023

16. Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma

Author

E&R onderzoek, CTC, Child Health, Urologie Medisch Kinderen, Cardiologie onderzoek 1, Circulatory Health, Regenerative Medicine and Stem Cells, Zorgeenheid Plastische Chirurgie Medisch, MS Dermatologie/Allergologie, Infection & Immunity, Hermans, Mireille M., Rietman, André B., Schappin, Renske, de Laat, Peter C.J., Mendels, Elodie J., Breur, Johannes M.P.J., Langeveld, Hester R., de Wildt, Saskia N., Breugem, Corstiaan C., de Graaf, Marlies, Raphael, Martine F., Pasmans, Suzanne G.M.A., E&R onderzoek, CTC, Child Health, Urologie Medisch Kinderen, Cardiologie onderzoek 1, Circulatory Health, Regenerative Medicine and Stem Cells, Zorgeenheid Plastische Chirurgie Medisch, MS Dermatologie/Allergologie, Infection & Immunity, Hermans, Mireille M., Rietman, André B., Schappin, Renske, de Laat, Peter C.J., Mendels, Elodie J., Breur, Johannes M.P.J., Langeveld, Hester R., de Wildt, Saskia N., Breugem, Corstiaan C., de Graaf, Marlies, Raphael, Martine F., and Pasmans, Suzanne G.M.A.

Published
2023

17. Correction to:Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma (European Journal of Pediatrics, (2022), 182, 2, (757-767), 10.1007/s00431-022-04674-7)

Author

Hermans, Mireille M., Rietman, André B., Schappin, Renske, de Laat, Peter C. J., Mendels, Elodie J., Breur, Johannes M. P. J., Langeveld, Hester R., de Wildt, Saskia N., Breugem, Corstiaan C., de Graaf, Marlies, Raphael, Martine F., and Pasmans, Suzanne G. M. A.

Abstract

In the original published version of the above article, the data reported with ‘yes’ and ‘no’ under "Child migration background" are switched up. The Table 1 below is the correct listing. (Table presented.) Participant characteristics All (n = 105) Propranolol (n = 36) Atenolol (n = 69) p-value Child age, years Median (IQR) 7.4 (6.7–8.5) 8.0 (7.3–8.8) 7.1 (6.4–8.1) 0.99 Male 20 (19) 7 (19) 13 (19) Child migration background a, n (%) Yes 10 (10) 0 (0.0) 10 (14) 0.01 No 94 (90) 36 (100) 58 (84) Unknown 1 (1.0) 0 (0.0) 1 (1.4) Education mother, n (%) Low 14 (13) 6 (17) 8 (12) 0.89 Average 28 (27) 8 (22) 20 (29) High 62 (59) 22 (61) 40 (58) Unknown 1 (1.0) 0 (0.0) 1 (1.4) Home language, n (%) Dutch 97 (92) 35 (97) 62 (90) 0.37 Other 2 (2.0) 0 (0.0) 2 (2.9) Multilingual 6 (5.7) 1 (2.8) 5 (7.2) Confirmed diagnosis, n (%) Attention deficit/hyperactivity disorder 6 (5.7) 3 (8.3) 3 (4.3) Location of IH b, n (%) Head and neck 84 (80) 24 (67) 60 (87) 0.02 Trunk 13 (12) 6 (17) 7 (10) 0.36 Genital area 13 (12) 7 (19) 6 (8.7) 0.13 Extremities 7 (6.7) 3 (8.3) 4 (5.8) 0.69 Ulcerated IH, n (%) Yes 29 (28) 13 (36) 16 (23) 0.16 No 76 (72) 23 (64) 53 (77) Treatment center, n (%) Erasmus MC 34 (32) 31 (86) 3 (4.3) c, years Median (IQR) 5.9 (5.2–6.5) 6.2 (5.6–6.6) 5.7 (5.1–6.2) 0.13 Range 1.6–9.7 1.6–9.7 4.5–8.4 p values indicate differences in participant characteristics between propranolol and atenolol group Continuous variables were not normally distributed and analyzed with a Mann-Whitney U test. Dichotomous variables were analyzed with a Fisher’s exact test aChild migration background, categorized as “yes” = one or both parents born abroad or “no” = both parents born in the Netherlands bA total of 105 patients had a total of 128 IH. The variable “location of IH” represents the number of children with at least one infantile hemangioma at each region cFollow-up time: time interval between cessation of beta-blocker treatment and neuropsychological assessment The original article has been corrected.

Published
2023
Full Text
View/download PDF

18. Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma

Author

Hermans, Mireille M., primary, Rietman, André B., additional, Schappin, Renske, additional, de Laat, Peter C. J., additional, Mendels, Elodie J., additional, Breur, Johannes M. P. J., additional, Langeveld, Hester R., additional, de Wildt, Saskia N., additional, Breugem, Corstiaan C., additional, de Graaf, Marlies, additional, Raphael, Martine F., additional, and Pasmans, Suzanne G. M. A., additional

Published
2022
Full Text
View/download PDF

19. Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma

Author

Hermans, Mireille M., primary, Breugem, Corstiaan C., additional, Schappin, Renske, additional, Jonge Poerink, Emma, additional, Mendels, Elodie J., additional, Ragamin, Aviël, additional, Breur, Johannes M.P.J., additional, Langeveld, Hester R., additional, Raphael, Martine F., additional, De Laat, Peter C.J., additional, De Wildt, Saskia N., additional, Rietman, André B., additional, Pasmans, Suzanne G.M.A., additional, and De Graaf, Marlies, additional

Published
2022
Full Text
View/download PDF

20. Late Mortality in Childhood Cancer Survivors according to Pediatric Cancer Diagnosis and Treatment Era in the Dutch LATER Cohort

Author

Kilsdonk, Ellen, van Dulmen-den Broeder, Eline, van Leeuwen, Flora E., van den Heuvel-Eibrink, Marry M., Loonen, Jacqueline J., van der Pal, Helena J., Bresters, Dorine, Versluys, A. B., Pieters, Rob, Hauptmann, Michael, Jaspers, Monique W.M., Neggers, Sebastian J.C., Raphael, Martine F., Tissing, Wim J.E., Kremer, Leontine C.M., Ronckers, Cécile M., Kilsdonk, Ellen, van Dulmen-den Broeder, Eline, van Leeuwen, Flora E., van den Heuvel-Eibrink, Marry M., Loonen, Jacqueline J., van der Pal, Helena J., Bresters, Dorine, Versluys, A. B., Pieters, Rob, Hauptmann, Michael, Jaspers, Monique W.M., Neggers, Sebastian J.C., Raphael, Martine F., Tissing, Wim J.E., Kremer, Leontine C.M., and Ronckers, Cécile M.

Abstract

This multi-center cohort-study examined late mortality among 6,165 Dutch five-year childhood cancer survivors diagnosed 1963–2001. Clinical details and cause of death were based on medical records. Mortality was 12-fold that of the general population, with 51.3 additional deaths per 10,000 person-years (21.9 yrs median follow-up). Cumulative mortality 15 yrs post-diagnosis was 6.9%, predominantly from late recurrences; thereafter the absolute contribution of other health outcomes increased. Cumulative all-cause and recurrence-related mortality were highest for Central Nervous System and bone tumor survivors. All-cause, but not subsequent tumor and circulatory disease-related cumulative mortality, was highest for patients diagnosed 1963–1979 vs. later (p-trend <0.001).

Published
2022

21. Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma

Author

Hermans, Mireille M., Breugem, Corstiaan C., Schappin, Renske, Jonge Poerink, Emma, Mendels, Elodie J., Ragamin, Aviël, Breur, Johannes M.P.J., Langeveld, Hester R., Raphael, Martine F., De Laat, Peter C.J., De Wildt, Saskia N., Rietman, André B., Pasmans, Suzanne G.M.A., De Graaf, Marlies, Hermans, Mireille M., Breugem, Corstiaan C., Schappin, Renske, Jonge Poerink, Emma, Mendels, Elodie J., Ragamin, Aviël, Breur, Johannes M.P.J., Langeveld, Hester R., Raphael, Martine F., De Laat, Peter C.J., De Wildt, Saskia N., Rietman, André B., Pasmans, Suzanne G.M.A., and De Graaf, Marlies

Abstract

Infantile haemangiomas are common benign tumours of infancy, which can be treated effectively with beta-blockers such as propranolol and atenolol. Different types of beta-blockers may result in different long-term aesthetic outcomes. This study evaluated the difference in long-term aesthetic outcomes between infantile haemangiomas treated with either propranolol or atenolol, including the perspective of physicians, parents, and children. Children, aged ≥6 years, treated with propranolol or atenolol for infantile haemangioma during infancy, participated in this 2-centre cross-sectional study. The primary endpoint was change in appearance of the infantile haemangioma from pre-treatment to follow-up, using a physician-rated visual analogue scale (VAS). Secondary outcomes were the Patient Observer Scar Assessment Scale (physician- and parent-rated) and a VAS (child-rated), assessing the residual lesion. In total, 103 children (35 treated with propranolol, 68 with atenolol) were analysed. No differences were found between children treated with propranolol and children treated with atenolol on physician-rated VAS (p = 0.10) or any secondary outcomes. Physicians indicated a large aesthetic improve-ment from pre- treatment to follow-up. Physicians, parents and children were positive about the current state of the residual lesion. Minor sequelae were common (86%). These results, in combination with the favourable safety profile of atenolol, should be considered when choosing beta-blocker treatment for infantile haemangioma.

Published
2022

22. Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma

Author

MS Dermatologie/Allergologie, Infection & Immunity, Cardiologie onderzoek 1, Child Health, Circulatory Health, Regenerative Medicine and Stem Cells, Hermans, Mireille M, Breugem, Corstiaan C, Schappin, Renske, Jonge Poerink, Emma, Mendels, Elodie J, Ragamin, Aviël, Breur, Johannes M P J, Langeveld, Hester R, Raphael, Martine F, De Laat, Peter C J, De Wildt, Saskia N, Rietman, André B, Pasmans, Suzanne G M A, De Graaf, Marlies, MS Dermatologie/Allergologie, Infection & Immunity, Cardiologie onderzoek 1, Child Health, Circulatory Health, Regenerative Medicine and Stem Cells, Hermans, Mireille M, Breugem, Corstiaan C, Schappin, Renske, Jonge Poerink, Emma, Mendels, Elodie J, Ragamin, Aviël, Breur, Johannes M P J, Langeveld, Hester R, Raphael, Martine F, De Laat, Peter C J, De Wildt, Saskia N, Rietman, André B, Pasmans, Suzanne G M A, and De Graaf, Marlies

Published
2022

29. Risico op trombose bij reactieve trombocytose

Author

Hengeveld, Paul J., Hazenberg, Mette D., Biezeveld, Maarten H., Raphael, Martine F., Clinical Haematology, CCA - Cancer biology and immunology, and Paediatric Oncology

Abstract

Reactive thrombocytosis (RT; thrombocyte count: > 450 x 109/l) is a condition in which an increase in platelet production, stimulated by cytokines in the bone marrow, is secondary to some condition or circumstance. Although RT does often occur in children, the risk of thromboembolic complications is negligible in this group if they have no other risk factors for thrombosis. In the absence of additional risk factors for thrombosis it seems as though RT in adults does not predispose them to thromboembolic complications either. Patients with RT caused by a non-myeloproliferative malignancy do have an increased risk of thromboembolic complications; antithrombotic prophylaxis might be effective in this group, but there is no scientific evidence for this. We advise a watch-and-wait approach in children and adults with RT who have no other risk factors for thromboembolism, even in patients with extreme thrombocytosis (thrombocyte count: > 1000 x 109/l). In patients who do have an increased risk of thromboembolic complications we advise tailoring prescription or non-prescription of antithrombotic prophylaxis to the individual patient.

Published
2018

31. Iron refractory iron deficiency anemia : a heterogeneous disease that is not always iron refractory

Author

Donker, Albertine E, Schaap, Charlotte C M, Novotny, Vera M J, Smeets, Roel, Peters, Tessa M A, van den Heuvel, Bert L P, Raphael, Martine F, Rijneveld, Anita W, Appel, Inge M, Vlot, Andre J, Versluijs, A Birgitta, van Gelder, Michel, Granzen, Bernd, Janssen, Mirian C H, Rennings, Alexander J M, van de Veerdonk, Frank L, Brons, Paul P T, Bakkeren, Dirk L, Nijziel, Marten R, Vlasveld, L Thom, Swinkels, Dorine W, Donker, Albertine E, Schaap, Charlotte C M, Novotny, Vera M J, Smeets, Roel, Peters, Tessa M A, van den Heuvel, Bert L P, Raphael, Martine F, Rijneveld, Anita W, Appel, Inge M, Vlot, Andre J, Versluijs, A Birgitta, van Gelder, Michel, Granzen, Bernd, Janssen, Mirian C H, Rennings, Alexander J M, van de Veerdonk, Frank L, Brons, Paul P T, Bakkeren, Dirk L, Nijziel, Marten R, Vlasveld, L Thom, and Swinkels, Dorine W

Published
2016

33. Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events - a review of the literature

Author

MS Dermatologie/Allergologie, Cardiologie patientenzorg, Regenerative Medicine and Stem Cells, Apotheek Klinische Farmacie, Zorgeenheid Plastische Chirurgie Medisch, Other research (not in main researchprogram), Raphael, Martine F, Breur, Johannes MPJ, Vlasveld, Florine AE, Elbert, Niels J, Liem, Yves Tb, Kon, Moshe, Breugem, Corstiaan C, Pasmans, Suzanne GMA, MS Dermatologie/Allergologie, Cardiologie patientenzorg, Regenerative Medicine and Stem Cells, Apotheek Klinische Farmacie, Zorgeenheid Plastische Chirurgie Medisch, Other research (not in main researchprogram), Raphael, Martine F, Breur, Johannes MPJ, Vlasveld, Florine AE, Elbert, Niels J, Liem, Yves Tb, Kon, Moshe, Breugem, Corstiaan C, and Pasmans, Suzanne GMA

Published
2016

34. Iron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractory

Author

MS Dermatologie/Allergologie, Haematologie patientenzorg, Child Health, Donker, Albertine E, Schaap, Charlotte C M, Novotny, Vera M J, Smeets, Roel, Peters, Tessa M A, van den Heuvel, Bert L P, Raphael, Martine F, Rijneveld, Anita W, Appel, Inge M, Vlot, Andre J, Versluijs, A Birgitta, van Gelder, Michel, Granzen, Bernd, Janssen, Mirian C H, Rennings, Alexander J M, van de Veerdonk, Frank L, Brons, Paul P T, Bakkeren, Dirk L, Nijziel, Marten R, Vlasveld, L Thom, Swinkels, Dorine W, MS Dermatologie/Allergologie, Haematologie patientenzorg, Child Health, Donker, Albertine E, Schaap, Charlotte C M, Novotny, Vera M J, Smeets, Roel, Peters, Tessa M A, van den Heuvel, Bert L P, Raphael, Martine F, Rijneveld, Anita W, Appel, Inge M, Vlot, Andre J, Versluijs, A Birgitta, van Gelder, Michel, Granzen, Bernd, Janssen, Mirian C H, Rennings, Alexander J M, van de Veerdonk, Frank L, Brons, Paul P T, Bakkeren, Dirk L, Nijziel, Marten R, Vlasveld, L Thom, and Swinkels, Dorine W

Published
2016

35. Iron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractory

Author

Donker, Albertine E., primary, Schaap, Charlotte C.M., additional, Novotny, Vera M. J., additional, Smeets, Roel, additional, Peters, Tessa M. A., additional, van den Heuvel, Bert L. P., additional, Raphael, Martine F., additional, Rijneveld, Anita W., additional, Appel, Inge M., additional, Vlot, Andre J., additional, Versluijs, A. Birgitta, additional, van Gelder, Michel, additional, Granzen, Bernd, additional, Janssen, Mirian C.H., additional, Rennings, Alexander J.M., additional, van de Veerdonk, Frank L., additional, Brons, Paul P.T., additional, Bakkeren, Dirk L., additional, Nijziel, Marten R., additional, Vlasveld, L. Thom, additional, and Swinkels, Dorine W., additional

Published
2016
Full Text
View/download PDF

37. Prevention of central venous catheter-associated bloodstream infections in paediatric oncology patients using 70% ethanol locks: A randomised controlled multi-centre trial

Author

Schoot, Reineke A., primary, van Ommen, C. Heleen, additional, Stijnen, Theo, additional, Tissing, Wim J.E., additional, Michiels, Erna, additional, Abbink, Floor C.H., additional, Raphael, Martine F., additional, Heij, Hugo A., additional, Lieverst, Jan A., additional, Spanjaard, Lodewijk, additional, Zwaan, C. Michel, additional, Caron, Huib N., additional, and van de Wetering, Marianne D., additional

Published
2015
Full Text
View/download PDF

40. Dyskeratosis Congenita: Evaluation of Immune Status and Hematopoietic Stem Cell Transplantation. A Literature and EBMT Data Base Survey of 75 Patients,

Author

Korthof, Elisabeth T, primary, Van der Zalm, Judith, additional, Raphael, Martine F, additional, Bresters, Dorine, additional, Tolar, Jakub, additional, Aljurf, Mahmoud, additional, Veys, Paul, additional, Oneto, Rosi, additional, Bacigalupo, Andrea, additional, Peters, Christina, additional, Gaspar, Bobby, additional, Dufour, Carlo, additional, and Marsh, Judith C. W., additional

Published
2011
Full Text
View/download PDF

42. What is the diagnosis?

Author

Steenhuijsen Piters, Wouter A A, Frenkel, Joost, Brand, Paul L P, and Raphael, Martine F

Subjects
EDUCATIONAL tests & measurements, PEDIATRICS, CONTINUING medical education
Abstract

The article describes how pediatricians, pediatric residents and researchers at three Dutch hospitals volunteered for a weekly e-mailed based quiz titled "What is the Diagnosis?" (WitD) as a way of encouraging continuing education. It focuses on how the program promoted knowledge acquisition and increased in popularity despite low response rates.

Published
2014
Full Text
View/download PDF

43. Late Mortality in Childhood Cancer Survivors according to Pediatric Cancer Diagnosis and Treatment Era in the Dutch LATER Cohort.

Author

Kilsdonk E, van Dulmen-den Broeder E, van Leeuwen FE, van den Heuvel-Eibrink MM, Loonen JJ, van der Pal HJ, Bresters D, Versluys AB, Pieters R, Hauptmann M, Jaspers MWM, Neggers SJC, Raphael MF, Tissing WJE, Kremer LCM, and Ronckers CM

Subjects
Bone Neoplasms mortality, Cause of Death, Child, Cohort Studies, Humans, Netherlands epidemiology, Cancer Survivors, Neoplasms diagnosis, Neoplasms epidemiology, Neoplasms mortality, Neoplasms therapy
Abstract

This multi-center cohort-study examined late mortality among 6,165 Dutch five-year childhood cancer survivors diagnosed 1963-2001. Clinical details and cause of death were based on medical records. Mortality was 12-fold that of the general population, with 51.3 additional deaths per 10,000 person-years (21.9 yrs median follow-up). Cumulative mortality 15 yrs post-diagnosis was 6.9%, predominantly from late recurrences; thereafter the absolute contribution of other health outcomes increased. Cumulative all-cause and recurrence-related mortality were highest for Central Nervous System and bone tumor survivors. All-cause, but not subsequent tumor and circulatory disease-related cumulative mortality, was highest for patients diagnosed 1963-1979 vs. later ( p -trend <0.001).

Published
2022
Full Text
View/download PDF

44. [Infantile haemangioma; refer and treat on time].

Author

van der Vleuten CJM and Raphael MF

Subjects
Adrenergic beta-Antagonists therapeutic use, Directive Counseling, Early Diagnosis, Hemangioma, Capillary pathology, Hemangioma, Capillary psychology, Humans, Infant, Parents psychology, Propranolol therapeutic use, Hemangioma, Capillary diagnosis, Hemangioma, Capillary therapy, Referral and Consultation
Abstract

Infantile haemangioma is a relatively common and usually benign condition that occurs in infancy. Nonetheless, during the growth phase in the first weeks or months of the child's life it can have a profound impact on both the patient and parents, especially when functional problems or complications occur. Care and attention by physicians is important at this stage; the information given by many healthcare practitioners that the infantile haemangioma will spontaneously disappear is often insufficiently reassuring and is not always correct. With the discovery of the therapeutic potential of oral beta-blockers, ten years ago, treatment has become more effective and more straightforward. Counselling on treatment with beta-blockers should be considered with low threshold. Consultation of a centre of expertise, possibly electronically, can facilitate timely referral so that growth of the infantile haemangioma can be stopped and complications may be prevented. Managing anxiety levels among parents/carers can be an important reason for consultation of a centre of expertise. During the growth phase of infantile haemangioma, careful monitoring is indicated, since time is of the essence for cases of infantile haemangioma with impending complications, associations or severe deformation.

Published
2019

45. [Risk of thrombosis in reactive thrombocytosis].

Author

Hengeveld PJ, Hazenberg MD, Biezeveld MH, and Raphael MF

Subjects
Adult, Child, Female, Humans, Male, Risk Factors, Thrombocytosis drug therapy, Fibrinolytic Agents therapeutic use, Thrombocytosis complications, Thromboembolism etiology, Thrombosis etiology
Abstract

Reactive thrombocytosis (RT; thrombocyte count: > 450 x 109/l) is a condition in which an increase in platelet production, stimulated by cytokines in the bone marrow, is secondary to some condition or circumstance. Although RT does often occur in children, the risk of thromboembolic complications is negligible in this group if they have no other risk factors for thrombosis. In the absence of additional risk factors for thrombosis it seems as though RT in adults does not predispose them to thromboembolic complications either. Patients with RT caused by a non-myeloproliferative malignancy do have an increased risk of thromboembolic complications; antithrombotic prophylaxis might be effective in this group, but there is no scientific evidence for this. We advise a watch-and-wait approach in children and adults with RT who have no other risk factors for thromboembolism, even in patients with extreme thrombocytosis (thrombocyte count: > 1000 x 109/l). In patients who do have an increased risk of thromboembolic complications we advise tailoring prescription or non-prescription of antithrombotic prophylaxis to the individual patient.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results